Update to the Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”)

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Study to Include Reeve Foundation North American Clinical Trials Network (NACTN) Registry

InVivo Therapeutics Holdings Corp. (NVIV) today announced that data from the Christopher & Dana Reeve Foundation NACTN Registry will be included in the Contemporary Thoracic SCI Registry Study (now called the “CONTEMPO Registry Study”), a complement to the ongoing INSPIRE study of the Neuro-Spinal Scaffold™. The CONTEMPO Registry Study is intended to provide comprehensive natural history benchmarks for INSPIRE study results that include spinal cord injury (SCI) patients with similar baseline characteristics treated since 2006. The NACTN registry is derived from a network of academic neurosurgical departments of hospitals that have a strong focus on SCI, especially in the acute injury phase. The NACTN Registry includes acute patient data such as pre- and post-operative data, post-injury complications and treatments, MRI data, and follow-up neurological exams. Because the NACTN registry contains acute care data, it will allow for the close matching of registry patient characteristics with INSPIRE inclusion and exclusion criteria, and will be highlighted in the CONTEMPO Registry Study as a well matched natural history benchmark comparator for INSPIRE results.

The CONTEMPO Registry Study will provide a robust evaluation of the recent natural history of acute, complete thoracic SCI patients across North American and European populations. InVivo has submitted a protocol for the CONTEMPO Registry Study to the U.S. Food and Drug Administration (FDA) and does not expect this study to affect clinical or regulatory timelines. InVivo believes that the combined information in the INSPIRE study and the CONTEMPO Registry Study will provide a rigorous body of evidence for the demonstration of safety and probable benefit as required by the Humanitarian Device Exemption (HDE) approval process, and plans to submit the two studies together for HDE approval.

James Guest, M.D., Ph.D., a member of InVivo’s Scientific Advisory Board, a NACTN investigator, and the Principal Investigator of the CONTEMPO Registry Study, said, “The NACTN Registry was developed in large part to aid in the interpretation of SCI clinical trial results. This is the first time that the registry will be used with a partner in industry, and I believe that the registry will provide a valuable benchmark for analysis of INSPIRE results.”

Mark Perrin, InVivo’s Chief Executive Officer and Chairman, added, “We are grateful for the care and vigilance that NACTN has put into developing an impressively thorough, curated database over many years. The inclusion of the NACTN Registry substantially increases the strength of the CONTEMPO Registry Study. We look forward to completing the INSPIRE study and the CONTEMPO Registry Study and submitting the results together in 2018 in an application for HDE approval of the Neuro-Spinal Scaffold.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles